The tender offer was completed at the low end of the price range ($5.00 vs $5.75 max), suggesting the market was willing to sell at the minimum price. The oversubscription and 55% proration indicate strong shareholder participation. Roivant's proportionate tender to maintain its 19.5% stake signals continued support from the largest shareholder. Watch for the final results press release and subsequent trading volume as the reduced float may increase price volatility.
Price Chart
Executive Summary
Arbutus Biopharma announced preliminary results of its $230M modified Dutch auction tender offer, expecting to purchase 46 million shares (approximately 23% of outstanding) at $5.00 per share, the low end of the $5.00-$5.75 range. The offer was oversubscribed with 65.9 million shares validly tendered, resulting in proration of approximately 55% for auction tenders at or below the purchase price. Roivant Sciences, a 19.5% shareholder, made a proportionate tender to maintain its ownership stake.
Key Financial Metrics
Key Facts
- Arbutus expects to purchase 46,000,000 shares at $5.00 per share for an aggregate purchase price of $230 million
- The tender offer represented approximately 23% of total issued and outstanding shares as of September 29, 2026
- 65,907,215 shares were validly tendered, making the offer oversubscribed
- Shareholders who tendered at or below $5.00 will have approximately 55% of their tendered shares purchased due to proration
- 9,307,231 shares are expected to be purchased via proportionate tenders (not subject to proration)
- Roivant Sciences Ltd., beneficial owner of 38,847,462 shares (19.5%), made a proportionate tender to maintain its ownership
- Following completion, approximately 153,275,907 shares will be outstanding
- The offer expired at 5:00 p.m. (New York City time) on September 29, 2026
Financial Impact
Company deploying $230 million to repurchase 23% of outstanding shares at $5.00 per share, reducing share count from ~199M to ~153M
Risk Factors
- The $230 million cash deployment reduces the company's cash runway for clinical-stage operations
- Preliminary results are subject to verification by the depositary and final results may differ
- Clinical-stage biopharma company with no approved products — reduced cash could pressure pipeline development
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-I/A Filing (Primary) | 0001104659-26-112115 |
| Document: tm2626584d1_ex99-a5iii.htm | 0001104659-26-112115 |
| Document: 0001104659-26-112115-index-headers.html | 0001104659-26-112115 |
| Document: 0001104659-26-112115-index.html | 0001104659-26-112115 |
| Document: 0001104659-26-112115.txt | 0001104659-26-112115 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $4.21 | awaiting T+60 | — | $4.20 (−0.24%) |
Oct 22, 2026 5d ago | Press Release | $4.21 | awaiting T+60 | — | $4.20 (−0.24%) |
Oct 7, 2026 20d ago | SC 13G/A | $4.18 | awaiting T+60 | — | $4.20 (+0.48%) |
Oct 5, 2026 21d ago | SC 13D/A | $4.48 | awaiting T+60 | — | $4.20 (−6.25%) |
Oct 1, 2026 26d ago | SC TO-I/A | $4.56 | awaiting T+60 | — | $4.20 (−7.89%) |
Oct 1, 2026 26d ago | Press Release | $4.56 | awaiting T+60 | — | $4.20 (−7.89%) |
Sep 30, 2026 27d ago | SC TO-I/A | $4.78 | awaiting T+60 | — | $4.20 (−12.13%) |
Sep 30, 2026 27d ago | Press Release | $4.78 | awaiting T+60 | — | $4.20 (−12.13%) |
Aug 21, 2026 9w ago | 8-K | $5.21 | awaiting T+60 | — | $4.20 (−19.39%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.71 | awaiting T+60 | — | $4.20 (−10.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers